metaPreg - Valsartan (versus unexposed) during pregnancy

Valsartan (versus unexposed) updated on 03-11-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	5.00 [1.57, 15.93]	-	1 study	21	30	not evaluable	ROB	9.48 [2.52; .]
Major congenital malformations	5.00 [1.57, 15.93]	-	1 study	21	30	not evaluable	ROB	9.48 [2.52; .]